HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$4.05 USD
-0.05 (-1.22%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $4.06 +0.01 (0.25%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.05 USD
-0.05 (-1.22%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $4.06 +0.01 (0.25%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 36.11% and 21.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of -12.50% and 8.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 14.75% and 7.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -233.33% and 93.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 21.74% and 84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of 9.52% and 10.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25% and 2.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -8.33% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of -3.63% and 12.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -22.64% and 9.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -12.96% and -26.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: HOOKIPA Pharma Inc. (HOOK) Q3 Earnings Expected to Decline
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers
by Zacks Equity Research
HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 0.00% and -1.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOOKIPA Pharma Inc. (HOOK) Soars 7.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 0.00% and 38.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for HOOKIPA (HOOK) This Earnings Season?
by Zacks Equity Research
HOOKIPA (HOOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
HOOKIPA Pharma Inc. (HOOK) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 17.86% and 0.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.